TScan Therapeutics

TScan Therapeutics

Biotechnology Research

Waltham, Massachusetts 7,797 followers

Unleash Immunity

About us

TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. TScan Therapeutics was founded in 2018 by a small group of scientists led by Dr. Stephen Elledge (Harvard Medical School/HHMI). TScan is discovering and developing novel TCR-engineered T cell therapies for the treatment of cancer. Our discovery platform is centered around a breakthrough technology that enables the rapid, comprehensive, and genome-wide identification of the peptide antigen targets of T cell receptors. This technology greatly enhances our ability to understand the specific antigens that drive important disease processes, including tumor cell recognition by the immune system, self-reactivity in autoimmune disorders, and acquired immunity in infectious disease. TScan is using the platform in oncology to discover new TCR/target pairs and to rapidly move novel TCRs into clinical development.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Waltham, Massachusetts
Type
Public Company
Founded
2018
Specialties
TCR-T Cell Therapy

Locations

Employees at TScan Therapeutics

Updates

Similar pages

Browse jobs

Funding

TScan Therapeutics 6 total rounds

Last Round

Post IPO equity

US$ 150.0M

See more info on crunchbase